Atyr PHARMA INC (NASDAQ:ATYR) Receives Average Recommendation of "Buy" from Analysts

Shares of Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) have received an average rating of "Buy" from the seven analysts that are covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $18.60.

Several research analysts recently commented on the stock. Leerink Partners assumed coverage on shares of Atyr PHARMA in a research note on Tuesday, February 18th. They set an "outperform" rating and a $16.00 price objective for the company. Leerink Partnrs raised Atyr PHARMA to a "strong-buy" rating in a research report on Tuesday, February 18th. Finally, HC Wainwright reissued a "buy" rating and issued a $35.00 price objective on shares of Atyr PHARMA in a research report on Friday, March 14th.

Atyr PHARMA Stock Down 1.2 %

NASDAQ:ATYR traded down $0.04 during trading hours on Friday, reaching $3.30. The company's stock had a trading volume of 241,792 shares, compared to its average volume of 1,287,294. The stock has a 50 day moving average price of $3.26 and a two-hundred day moving average price of $3.40. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41. The company has a market capitalization of $293.23 million, a P/E ratio of -3.51 and a beta of 0.79. Atyr PHARMA has a 12 month low of $1.42 and a 12 month high of $4.66.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.02. Equities analysts predict that Atyr PHARMA will post -0.91 EPS for the current fiscal year.

Institutional Investors Weigh In On Atyr PHARMA

A number of large investors have recently bought and sold shares of ATYR. Federated Hermes Inc. purchased a new position in shares of Atyr PHARMA during the fourth quarter worth $53,093,000. Point72 Asset Management L.P. purchased a new position in shares of Atyr PHARMA during the 4th quarter valued at about $17,677,000. Tikvah Management LLC acquired a new position in shares of Atyr PHARMA in the 4th quarter valued at about $8,908,000. Woodline Partners LP purchased a new stake in shares of Atyr PHARMA in the fourth quarter worth about $6,092,000. Finally, Alyeska Investment Group L.P. acquired a new stake in Atyr PHARMA during the fourth quarter worth about $4,628,000. Hedge funds and other institutional investors own 61.72% of the company's stock.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.